Geron Corporation
NMS: GERNLive Quote
📈 ZcoreAI Score
Our AI model analyzes Geron Corporation's price action across multiple timeframes using regression channels and statistical scoring.
Get GERN Z-Score →About Geron Corporation
Healthcare
Biotechnology
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
📊 Fundamental Analysis
Geron Corporation demonstrates a profit margin of -45.4%, which is below the sector average, suggesting competitive pressure.
The company recently reported 1.0% revenue growth, which is modest compared to its industry peers.
Return on Equity (ROE) is -33.0%, which indicates that capital utilization is currently under pressure.
At a current price of $1.67, GERN currently sits at the 65th percentile of its 52-week range (Range: $1.04 - $2.01).
🏥 Financial Health
🔴
Profit Margin
Weak
⚠️
Debt/Equity
Moderate
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$1.07B
Trailing P/E
--
Forward P/E
20.88
Beta (5Y)
0.67
52W High
$2.01
52W Low
$1.04
Avg Volume
18.04M
Day High
Day Low